Nanopore Based Biological Sensor for Detection of Prostate Cancer

Period of Performance: 11/14/2005 - 05/13/2006


Phase 1 SBIR

Recipient Firm

Lynntech, Inc.
Principal Investigator


Prostate cancer, the second most common cancer in men, is the most commonly diagnosed cancer in the United States. PSA is used widely as a serum marker for the early detection of prostate cancer and for monitoring disease recurrence after therapy. However, the use of the biomarker has been criticized as well and the controversy remains unresolved. The major drawback of PSA screening is its relative wide "gray zone", where PSA screening has false negative or false positive. Better screening and monitoring biomarkers are needed and extensive studies have been carried out to develop novel effective biomarkers. This proposal concerns the development of novel biomarker screening for prostate cancer diagnosis, implementing emerging nanotechnology into well established antibody-based detection method to overcome the drawback of PSA screening. This nanopore-based biological sensor consists of multiple antibodies to detect multiple biomarkers to enhance the specificity of screening for prostate cancer. Phase I effort will demonstrate the feasibility of the proposed technology by fabricating and evaluating a nanopore-based biosensor to detect new biomarker. Further development of the technology toward array structured sensor will be started in Phase I Option and Phase II effort.